2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma

NCT03004287 Phase 2 ACTIVE_NOT_RECRUITING

This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects

Details

Lead sponsor	University of Arkansas
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	50
Start date	2017-07-01
Completion	2027-10

Conditions

• Multiple Myeloma

Interventions

• Carfilzomib
• Thalidomide
• Dexamethasone
• Daratumumab
• Cisplatin
• Adriamycin
• Cyclophosphamide
• Etoposide
• Melphalan
• ASCT

Primary outcomes

• Measure the progression-free survival in patients with high risk multiple myeloma — 48 months

Countries

United States